

May 2, 2024

Τo

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

То

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001**

Company Code No. 524804

Dear Sir / Madam.

Sub: Purchase of shares of a JV company by a step-down subsidiary of the Company and make it as a wholly owned step-down subsidiary.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that Aurogen South Africa Pty Limited, South Africa, a wholly owned step-down subsidiary of the Company, has entered into agreement with the shareholders of Purple Bellflower Pty Limited, South Africa, a joint venture company, to purchase entire shares held by other joint venture partners and make Purple Bellflower Pty Limited a wholly owned subsidiary of Aurogen South Africa Pty Ltd, and also Aurobindo Pharma Pty Limited, South Africa, a wholly owned subsidiary of Aurogen South Africa Pty Limited.

Additional disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure**.

Please take the information on record.

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Enclosures: Annexure

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.



Annexure

_	Name of the target entity details in brief auch as	Durolo Dallflouer F	ty Limited Car	th Africa (DDI	E) is a laint Vantura
а	Name of the target entity, details in brief such as size, turnover etc.;	Purple Bellflower Pty Limited, South Africa (PBF), is a Joint Venture Company.			
		48% shares of PBF are held by Aurogen South Africa Pty Limited, South Africa (ASL), a wholly owned step-down subsidiary of the Company and 52% shares are held by other Joint Venture Partners.			
		Now, ASL purchased entire shares held by other Joint Venture Partners in PBF.			
		PBF was incorporated on August 23, 2018 and it has no turnover and was incorporated for the purpose of holding investments in other subsidiaries and joint ventures in the region.			
		PBF is holding 50% shares in Aurobindo Pharma Pty Limited, South Africa (APSA) and the balance 50% shares are held by ASL.			
		APSA has been doing Antiretroviral (ARV) business in South Africa and its brief financials are as follows: (INR Millions)			
		Year ending on	Turnover	PAT	Net worth
		31-Mar-23	2676.10	26.45	259.02
		31-Mar-24	2558.35	58.55	312.39
		With the acquisition 100% step-down su	of 52% in PBF,	both PBF and /	
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The other Joint Venture Partners of PBF from whom the shares are acquired by ASL are not related parties of PBF, ASL, APSA and the Company.			
С	Industry to which the entity being acquired belongs;	An investment company for making investments in entities engaged in manufacturing / marketing of pharmaceutical products in the region.			
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To consolidate its investment and to make PBF and in turn APSA, wholly owned step-down subsidiaries of the Company.			
е	Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental or regulatory approvals required.			
f	Indicative time period for completion of the acquisition;	Transaction is completed on April 30, 2024.			
g	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration			
h	Cost of acquisition and/or the price at which the shares are acquired;	INR 119.03 million (in ZAR 26.51 m	illion)	
-					

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190) www.aurobindo.com PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.



i	Percentage of shareholding / control acquired and / or number of shares acquired;	52%
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	PBF is a Joint Venture Company in which ASL holds 48% of the total share capital and it was incorporated on August 23, 2018. PBF has no direct commercial activities and is holding investment in APSA.

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370/23747340 Fax: +91 40 2374 1080/2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com